Evaluation of a Polyherbal Formulation on the Management of Migraine Headaches due to Functional Dyspepsia: A Double-Blind, Randomized, Placebo-Controlled Clinical Trial

Table 2

The effects of different interventions on the levels of frequency, duration and severity of the disease.

Group No	Variable	Week 0	Week 4	Week 8	Week 12	-value	Difference in week 0 and 12
1	Frequency	7.21 ± 4.65	3.73 ± 2.47	2.95 ± 1.77	2.34 ± 1.11		4.86 ± 4.37
2		5.82 ± 2.60	3.30 ± 1.76	3.21 ± 2.15	2.73 ± 1.68		3.08 ± 2.44
3		6.86 ± 3.80	4.13 ± 2.47	3.36 ± 1.52	3.13 ± 1.48		3.72 ± 3.39
1	Duration	30.86 ± 16.27	13.52 ± 12.84	5.86 ± 3.75	6.86 ± 5.48		24 ± 15.81
2		31.08 ± 20.96	12.95 ± 8.33	10.34 ± 6.59	7.43 ± 5.40		23.65 ± 18.73
3		23.04 ± 15.42	9.54 ± 6.92	6.90 ± 5.19	6.31 ± 5.29		16.72 ± 13.58
1	Severity	8.04 ± 1.71	5.71 ± 2.05	4.48 ± 2.56	3.91 ± 1.31		4.13 ± 2.13
2		8.17 ± 0.98	6.69 ± 3.99	5.78 ± 4.16	4.52 ± 2.23		3.65 ± 2.49
3		8.22 ± 1.30	5.09 ± 2.02	5.22 ± 2.59	4.68 ± 2.58		3.54 ± 2.73

Data were presented as mean and standard deviation (SD). value of variable changes within the group was calculated based on the Friedman test; value of frequency, duration, and severity of differences in week 0 and week 12 between groups was calculated based on the Kruskal-Wallis test. Group 1: the poly-herbal formulation capsule 1500 mg (two capsules of 750 mg) three times a day,  + Depakine® tablet 200 mg twice a day + Amitriptyline tablet 10 mg once a day; Group 2: Depakine® tablet 200 Mg twice a day + Amitriptyline 10 mg once a day + the poly-herbal formulation placebo capsule three times a day; Group 3: the poly-herbal formulation capsule 1500 mg (two capsules of 750 mg) three times a day + Depakine® placebo tablet twice a day.